Back to News & Events

Long Island Bioscience Hub Announces Funded Projects

Accelerating Biomedical Discoveries for Commercialization

STONY BROOK, N.Y. – December 7, 2015 – The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory.

The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards.

Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology.  Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization.

The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are:

Feasibility awards

  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors – Dr. Carol Carter
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer – Dr. Michael Frohman
  • Novel miR-129 Based Therapeutics for Colon Cancer – Dr. Jingfang Ju
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes – Dr. Dima Kosakov
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs – Dr. Gabriel Pagnotti
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration – Dr. Yixian Qin
  • LDL as Biomarker for Childhood Tuberculosis (TB) – Dr. Xinxin Yang

Proof of Concept awards

  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology – Dr. Marcous Abboud
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams – Dr. Avraham Dilmanian
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) – Dr. Amirhossein Goldan
  • Azasteroids for Combination Anti-TB Therapy – Dr. Nicole Sampson
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre – Dr. Eckard Wimmer

​“We are excited to see such a robust and diverse portfolio of early stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.”

The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3107 [post_author] => 3 [post_date] => 2018-12-18 16:28:18 [post_date_gmt] => 2018-12-18 16:28:18 [post_content] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019. Did you know that the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) SBIR/STTR programs award over $2.6 billion in high-risk, non-diluted R&D funding annually to qualified small businesses? Learn more about SBIR/STTR funding at this 1.5-day session focused on the National Institutes of Health (NIH) which will cover program essentials and how to compete for funding. Training will include: – Current information on the SBIR/STTR programs – Strategies for targeting your proposal to address the mission and requirements of the NIH – How to approach each section of your proposal – Planning your commercialization strategy – Writing to meet the reviewers’ expectations Tuesday, January 15, 2019, 8:30am – 4:30pm Wednesday, January 17, 2019, 8:30am –12:00pm Location: Long Island High Technology Incubator Main Conference Room 25 Health Sciences Drive Stony Brook, NY 11794 Registration Fee: $60 | Space is Limited. Pre-registration is required. REGISTER ONLINE [post_title] => SBIR/STTR INTENSIVE WORKSHOP: NIH FOCUSED [post_excerpt] => The Center for Biotechnology will be hosting our annual SBIR/STTR NIH Focused Workshop on January 15-16, 2019. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbirsttr-intensive-workshop-nih-focused [to_ping] => [pinged] => [post_modified] => 2019-01-24 15:35:16 [post_modified_gmt] => 2019-01-24 15:35:16 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3107 [menu_order] => 107 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4519 [post_author] => 4 [post_date] => 2024-11-08 11:33:54 [post_date_gmt] => 2024-11-08 16:33:54 [post_content] =>

The CFB was proud to support our clients, Ergami Endoscopy and FASS, who were each announced as winners of $50,000 after pitching their business plans to a panel of judges assembled by FuzeHub at the recent New York State Innovation Summit.

FuzeHub is a not-for-profit organization that supports small and medium-sized manufacturing companies in New York State, hosts this annual as part of the ESD-supported FuzeHub Jeff Lawrence Innovation Fund.

Ergami Endoscopy, based in New York City, is developing a low-cost robotic colonoscope insertion solution to improve procedure productivity; reduce patient pain and need for sedation; and reduce endoscopy-related injuries in endoscopists and nurses.

FASS is a unique syringe system that uses a rotating mechanism to switch between two needles in a single device, eliminating the need for manual switching of needles. Developed by an ER nurse after witnessing the dangers of needlestick injuries firsthand, FASS is designed to improve safety and efficiency in high-pressure environments like the ER and psychiatric units, where patients can be agitated.

Read more about the competition here.

[post_title] => CFB Clients Tapped as FuzeHub Commercialization Competition Winners [post_excerpt] => The CFB was proud to support two clients in efforts in the FuzeHub Commercialization Competition. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-clients-tapped-as-fuzehub-commercialization-competition-winners [to_ping] => [pinged] => https://fuzehub.com/manufacturing-blog/fuzehub-announces-2024-new-york-state-innovation-summit-commercialization-competition-winners/ [post_modified] => 2025-05-01 12:38:12 [post_modified_gmt] => 2025-05-01 16:38:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4519 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4224 [post_author] => 4 [post_date] => 2023-07-10 11:47:37 [post_date_gmt] => 2023-07-10 15:47:37 [post_content] =>

The Center for Biotechnology at Stony Brook University (CFB) has announced the recipients of the 2023-2024 Applied Research & Development (ARaD) awards. The ARaD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry.

The CFB is supporting the project*, “Wearable Haptic Device for Catheter Based Cardiac Procedures” that is being developed by HapticHeart Solutions. The company is collaborating with Dr. Wei Lin of the Department of Biomedical Engineering to upgrade the haptic handle of their current prototype to a sleek wearable device for a better experience and reduced cost. The technology has the potential to revolutionize the $14B cardiac catheterization market.

Additionally, the CFB will support the project* entitled “"Development of a Structural Model and Enzyme-Inhibitor Interactions for a Novel Cancer Target” by Lime Therapeutics, a startup spun out of Memorial Sloan Kettering Cancer Center, in collaboration with Dr. Ivet Bahar, who serves as the Louis and Beatrice Laufer Chair and Director Laufer Center for Physical & Quantitative Biology within the Department of Biochemistry and Cell Biology at Stony Brook University. The goal of this project is to leverage the computational and molecular dynamics capabilities of Dr. Bahar’s lab to achieve three specific aims related to optimizing the company’s lead compound.

The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

Companies that are looking to connect with expertise at Stony Brook University are encouraged to contact Dr. Phuong Nguyen at the Center for Biotechnology to explore options. Dr. Nguyen can be reached at: phuong.t.nguyen@stonybrook.edu.

*pending finalization of contract

View the full press release here.

[post_title] => CFB Announces Annual Applied Research & Development (ARaD) Awards [post_excerpt] => The CFB has announced the recipients of the 2023-2024 Applied Research & Development (ARaD) awards, projects include a “Wearable Haptic Device for Catheter Based Cardiac Procedures” and the "“Development of a PAFAH2 Structural Model and PAFAH2-Inhibitor Interactions”. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => arad-2023 [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:33:15 [post_modified_gmt] => 2024-08-22 15:33:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4224 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 270 [max_num_pages] => 90 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

SBIR/STTR INTENSIVE WORKSHOP: NIH FOCUSED

More Information

CFB Clients Tapped as FuzeHub Commercialization Competition Winners

More Information

CFB Announces Annual Applied Research & Development (ARaD) Awards

More Information